Tumor Mutation Load and Biomarker Data for 4125 Gastrointestinal Cancers

4125 tumor samples from 14 gastrointestinal cancer sites were analyzed for tumor mutation load (TML), microsatellite instability (MSI), and PD-L1 expression. The data originates from a research study by Mohamed E. Salem, published in 2020, quantifying these biomarkers and their interrelationships. It includes findings such as TML-high prevalence ranging from 0% in GIST to 14.6% in right-sided colon cancer.

Use Cases

• Analyze the correlation between TML-high status and MSI-H status across 14 different gastrointestinal cancer sites.
• Investigate the relationship between PD-L1 expression levels and microsatellite instability status (MSI vs. MSS).
• Compare the prevalence of TML-high tumors, such as the 14.6% rate in right-sided colon cancer versus 1.3% in pancreatic neuroendocrine tumors.
• Model potential immunotherapy response predictors by integrating TML, MSI, and PD-L1 expression data from 4125 samples.

Strengths

• Contains biomarker data for 4125 tumor samples, providing a substantial cohort for analysis.
• Covers 14 distinct gastrointestinal cancer sites, enabling comparative studies across cancer types.
• Includes three key immunotherapy biomarkers: tumor mutation load (TML), microsatellite instability (MSI), and PD-L1 expression.
• Data is derived from next-generation sequencing and immunohistochemistry on formalin-fixed paraffin-embedded (FFPE) samples.

Limitations

• The dataset is from a single 2020 study, so findings may not reflect the latest clinical biomarkers or treatments.
• Specific column definitions and raw data formats are not provided in the input, limiting immediate analytical use.
• The geographic origin and demographic details of the patient cohort are not specified, which may limit generalizability.

Provenance

Source

Dryad digital repository, from a study by Mohamed E. Salem.

Collection Method

Next-generation sequencing of genomic DNA from FFPE tumor samples using a 592-gene panel; MSI assessment via direct analysis of loci; PD-L1 expression via immunohistochemistry.

Freshness

Last updated 2020-06-24.